Neobutin Retard, 300 mg 60 pcs

Name: Neobutin Retard, 300 mg 60 pcs
SKU: 504068
Availability: InStock

€26.45

EAN: 4605077007462 SKU: 504068 Categories: Medicine, Pain and fever, Pain and spasms

Description

Pharmacotherapeutic group: antispasmodic agent.

ATX code: [A03AA05]

Pharmacological properties

Pharmacodynamics

Trimebutin, acting on the enkephalinergic system of the intestine, is a regulator of its peristalsis. Acting on peripheral δ-, μ- and κ receptors, including those located directly on the smooth muscles throughout the gastrointestinal tract (GIT), it regulates motility without affecting the central nervous system. Thus, trimebutine restores normal physiological activity of the intestinal muscles in various GI diseases associated with motility disorders.

Normalizing visceral sensitivity, trimebutine provides analgesic effect in abdominal pain syndrome.

Pharmacokinetics

Absorption and distribution.

After oral administration, trimebutin is rapidly absorbed from the gastrointestinal tract. The volume of distribution (Vd) is 88 liters. The degree of binding to plasma proteins is low – about 5%. Trimebutine penetrates through the placental barrier to a small extent.

Metabolism and excretion.

Trimebutine is biotransformed in the liver and excreted in the urine mainly as metabolites.

Indications

Symptomatic treatment of pain, abdominal cramps and discomfort, bloating (flatulence), bowel motor disorders with changes in stool frequency (diarrhea or constipation), dyspepsia, heartburn, belching, nausea, vomiting associated with functional diseases of the gastrointestinal tract and biliary tract (non-erosive form of gastroesophageal reflux disease; cholelithiasis; biliary tract dysfunction; irritable bowel syndrome; Oddi sphincter dysfunction, postcholecystectomy syndrome). Postoperative paralytic intestinal obstruction.

Active ingredient

Trimebutin

Composition

1 tablet contains:

active ingredient: trimebutine maleate 300 mg;

excipients: lactose monohydrate, tartaric acid, hypromellose (hydroxypropyl methylcellulose), povidone K30, colloidal silicon dioxide (aerosil), magnesium stearate.

Hypromellose (hydroxypropyl methylcellulose), talc, Opaspray white M-1-7111 [titanium dioxide, denatured ethanol (methylated alcohol), hypromellose-2910, water], silicon defoamer.

How to take, the dosage
How to take, the dosage
Ingestion, before meals.
Adults and children over 12 years of age take 300 mg twice daily.
The maximum daily dose is 600 mg.

Interaction
Interaction
Drug interaction of the drug Neobutin® Retard has not been described.

Special Instructions
Special Instructions
The recommended course of treatment of irritable bowel syndrome in the acute period is 600 mg per day for 4 weeks.
Influence on driving and operating ability
The drug Neobutin^® Retard has no sedative effect, does not affect psychomotor reactions and can be used in a variety of occupations, including those requiring increased attention and coordination of movements. However, given the possible side effects that may affect the above abilities (dizziness and others), caution should be exercised when driving motor vehicles and engaging in other potentially hazardous activities.

Synopsis
Synopsis
Oblong-shaped, rounded-edged, biconvex, film-coated tablets, white or almost white.

Contraindications
Contraindications
Hypersensitivity to the ingredients of the drug.
Children under 12 years of age.
Pregnancy.
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Side effects
Side effects
Digestive system disorders: Dry mouth, unpleasant taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation.
Nervous system disorders: sleepiness, fatigue, dizziness, headache, restlessness, weakness, feeling hot or cold.
Allergic reactions: cutaneous allergic reactions.
Other: menstrual irregularities, painful enlargement of the breasts, urinary retention.

Overdose
Overdose
To date, no cases of trimebutine overdose have been reported.

Pregnancy use
Pregnancy use
Pregnancy Experimental studies have shown no data on teratogenicity and embryotoxicity of trimebutine. However, due to the lack of necessary clinical data, the use of trimebutine during pregnancy is contraindicated.
Breastfeeding period Trimebutine is not recommended during breastfeeding, due to a lack of reliable clinical data confirming the safety of trimebutine during this period. If it is necessary to use trimebutine during breastfeeding, breastfeeding should be stopped.

Similarities
Similarities
Trimedat, Trimedat for children, Trimedat Forte

Additional information
Weight 0.066 kg
Shelf life
3 years. Do not use after the expiration date stated on the package.
Conditions of storage
Store at a temperature not exceeding 25 oC. Keep out of reach of children.
Manufacturer
Alium JSC, Russia
Medication form
sustained release tablets
Brand
Alium JSC